No abstract

Despite the threat of coronavirus infection, the Siddha system of medicine, India's traditional medicine, plays an important role in southern India, particularly in Tamilnadu. It contributed considerably not only in the first wave of Covid-19, but also in the second wave. The Government of Tamilnadu developed Siddha COVID-19 treatment centers for asymptomatic, mild, and moderate COVID-19 positive patients in 2020. The TPEC COVID Care Centre initiated at Vellore also one of the Centers that can be managed by Siddha medicines and Siddhar’s Yogam. As of July 14, 2021, about 4525 COVID positive patients had been treated with Siddha integrated treatment at Vellore alone in the first and second waves. Kaba Sura Kudineer, Thalisathy Vadagam, Amukkara Chooranam Mathirai, Bramanandha Bairavam Mathirai, and Adathodai Manapagu are indeed the five Siddha classical preparations used to manage the symptoms of COVID-19 positive patients at TPEC COVID Care Centre in Vellore. This Siddha medical practice is effective in conditions of symptoms and helps in the reduction of clinical outcomes. A pilot study at the same site confirmed the Siddha classical preparation's safety and effectiveness. A feedback analysis study performed at the same center also revealed that the above-mentioned Siddha classical preparations are beneficial in symptomatic treatment without causing any side effects. The medicines utilized in this study are typically proposed in other COVID care centers also in Tamilnadu. This review attempted to analyze the preclinical and clinical efficacy of Siddha Classical medicines used at that Centre for the management of COVID-19.

Siddha Clinical Research Unit (SCRU) Tirupati, working under the Central Council for Research in Siddha (CCRS), Ministry of AYUSH, Govt. of India, conducted a National Web conference titled “Integrated Siddha Approach in Clinical Practice and Research on COVID-19 Pandemic (ISACC)” on 23^rd Dec 2020, as a part of the fourth Pre-Siddha Day observance. Totally, 256 participants from Siddha colleges and various institutes of CCRS attended the Web conference and 9 eminent Speakers share their knowledge at the conference. The Technical session was separated by three panels, (i)Siddha Standalone and Integrative Clinical trials on COVID-19, (ii)Siddha Preventive and Prophylactic Measures on COVID-19, (iii)Experiences in Siddha Integrative Clinical Practice on COVID-19. The take home message of the conference insisted upon the three facts - the need for more clinical trials , need for increased experience sharing platforms for Siddha medical system and finally that Siddha standalone as well as integration for COVID-19 management gave significant outcome in both preventive and promotive healthcare. Central Council for Research in Siddha (CCRS), Ministry of AYUSH, Govt. of India and Directorate of Indian Medicine and Homeopathy (DIM&H), Government of Tamil Nadu, contributed a lot in Research and services in COVID-19 pandemic.

In India, according to WHO 2018 statistics, there were 63% of death occurred due to Non-communicable diseases (NCDs), in which Cardiovascular diseases were leading cause of death 27%, followed by Cancer 9%, Chronic respiratory disease 11%, Diabetes 3% and other NCDs 13%. This indicates that NCDs needs to become a priority in controlling and preventing. Therefore, the only effective intervention may be at controlling and preventing NCDs disease is Integrative Medicine. Integrative Medicine is a medical practice synthesizing Traditional medicine and Biomedicine preventive measures and treatment interventions. Autonomy of patients may end in no benefit out of their ignorance to select between the treatment options available in a country like India where Seven Recognized medical systems are available as a platter. Siddha system of medicine is one of the traditional medicines of India, practiced in the southern part of the country. This study aims at providing Health care system under one roof, in order to save public money, time and health as an existing model as co-location in Tamil Nadu. This can be achieved through assessing feasible areas of integration in the Siddha system of medicine with biomedicine. So the study deals with the utilization of Siddha system of medicine, scientific validation of Siddha medicines, Siddha medicine research undertaken by biomedical practitioners and some government policies supporting mainstreaming of Siddha.

No abstract

No abstract

No Abstract.

Aim: The patients with psoriasis, like those with other major medical disorders, have reduced levels of employment and income as well as a decreased quality of life. The treatments such as methotrexate, cyclosporine have been used for many years, but the safety profile of this treatment is minimal. Hence an idea is created to conduct a clinical trial to assess the efficacy and safety of Siddha trial drugs "Panchamuga Chendhuram" (PMC) and "Kundavaadhi Thailam" (KVT) in the management of psoriasis. Materials and methods: 40 patients of either sex was divided into 2 groups. The Group I treated with PMC alone at 65mg dose twice daily, for 48 days. The Group II treated with both PMC and KVT. Efficacy was determined by a percentage reduction in Psoriasis Area and Severity Index (PASI) score. Safety of drug PMC was evaluated by measuring LFT and RFT. Results: PASI Score Mean and SEM (n) at 48 th day after treatment with the trial drug PMC alone and with both PMC and KVT were 2.295 ± 0.531 * (20), 5.305 ± 1.982 * (20) respectively, and P value <0.001 is statistically significant. Safety parameters such as T. Bilirubin (P < 0.05), T. Protein (P = 0.361), SGPT (P = 0.798), SGOT (P < 0.05), ALP (P = 0.436), urea (P= 0.810), creatinine (P = 0.207), uric acid (P = 0.836) were also have no changes before and after treatment. Conclusion: Hence it is concluded that the drugs were effective and safe in psoriasis patients.